Raloxifene Administration in Women Treated with Long Term Gonadotropin-releasing Hormone Agonist for Severe Endometriosis: Effects on Bone Mineral Density
Journal of Menopausal Medicine
; : 174-179, 2016.
Article
em En
| WPRIM
| ID: wpr-10050
Biblioteca responsável:
WPRO
ABSTRACT
OBJECTIVES: To evaluate the efficacy of raloxifene in preventing bone loss associated with long term gonadotropin-releasing hormone agonist (GnRH-a) administration. METHODS: Twenty-two premenopausal women with severe endometriosis were treated with leuprolide acetate depot at a dosage of 3.75 mg/4 weeks, for 48 weeks. Bone mineral density (BMD) was evaluated at admission, and after 12 treatment cycles. RESULTS: At cycle 12 of GnRH-a plus raloxifene treatment, lumbar spine, trochanter femoral neck, and Ward's BMD differed from before the treatment. A year after treatment, the lumbar spine and trochanter decreased slightly, but were not significantly different. CONCLUSIONS: Our study shows that the administration of GnRH-a plus raloxifene in pre-menopausal women with severe endometriosis, is an effective long-term treatment to prevent bone loss.
Palavras-chave
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Coluna Vertebral
/
Densidade Óssea
/
Hormônio Liberador de Gonadotropina
/
Leuprolida
/
Cloridrato de Raloxifeno
/
Endometriose
/
Fêmur
/
Colo do Fêmur
Limite:
Female
/
Humans
Idioma:
En
Revista:
Journal of Menopausal Medicine
Ano de publicação:
2016
Tipo de documento:
Article